Ozow - Paving the Way for Open Banking in Africa
28.7.2020 08:00:00 EEST | Business Wire | Press release
“In a constantly changing global economy, traditionally dominated by large banks since 1472, (something which is unlikely to change in the coming decades), Ozow is positioned as a disruptor to challenge the status quo. Ozow is leading the way with an Open Banking platform in Africa, and the startling growth of the business over the past 6 years tells the story of a fast growing start up on the verge of taking the African continent by storm,” says Ozow CEO and co-founder, Thomas Pays. “As a market led company Ozow’s success has grown to see them capturing an entire market (representing over 70% of the instant EFT market in South Africa), from the heart of underprivileged townships and rural areas to the highest LSM. Users all note that the payment platform is a better, safer, and easier alternative to cards or a manual EFT payment”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005804/en/
Ozow Co-founders; Mitchan Adams, Thomas Pays, Lyle Eckstein (Photo: Business Wire)
There are over 49 million bank accounts in South Africa alone – users just need a convenient way to pay from them. This is where Ozow’s secure online payments platform is leading payment innovation.
“Consumers, merchants, and banks in South Africa and Namibia now recognize Ozow as the quick and trusted way to make payments,” says Pays. “As most people in the region go online mainly through their mobile devices (the same rings true for the rest of Africa) – and often pre-pay for airtime/data – transaction speed is essential. We commit to enabling payments in a few seconds.”
Ozow’s latest product release in the form of a world first, patent-pending innovation called the Ozow PIN has also resulted in increased growth of the business. This technology empowers a user to tokenize payment and make any repeat purchases with the simple entry of a 4-digit PIN. This world first innovation is already aggressively taking the lion’s share of the cash, card, and alternative payment options market by empowering users to transact anytime, anywhere online, or at point of sale, without the need for an app or registration. “As a market leading payments company in Africa, we have put the needs of our clients first, resulting in an increase of over 50% in recurring payments since the introduction of this new technology,’’ says Pays. Ozow can also be used for e-billing in partnership with SAGE and Xero, SMS payments via all major networks, and QR codes. The service is becoming available in five of South Africa’s 11 official languages, with plans to add the other languages in the coming months.
From the merchant’s perspective, Ozow acts as an additional layer of security to that of the existing banking infrastructure, keeping all transactions ultra-safe at all times and providing an environment that has proven to be safer than any other payment mechanism. Once a payment has been confirmed, it is irrevocable, using a real-time digital instruction issued by the owner of the source account.
Ozow was founded in 2014 by Mitchan Adams and Lyle Eckstein (both South African) together with CEO Thomas Pays, a Frenchman who has lived in South Africa for more than 16 years.
The past few years has seen Ozow become the most trusted payment brand among users who have developed a strong emotional attachment to the brand, empowering many to transact digitally for the first time.
Ozow’s company values and the culture it has developed focuses on empowering its stakeholders and being impactful. In April last year Ozow introduced a “0% fees’’ campaign for NPO/NGO’s as well as SME’s, again leading the way in the market as a socially responsible business, by passing value on to entrepreneurs (a critical element of the South African economy) who often place their customer’s needs ahead of their own.
“Today, Ozow is a team of 50 + people who share a vision of bringing our fast and easy payment solutions to the African continent and ultimately the globe. Through Ozow, in a market where over ZAR9,7 trillion is transferred via “bank to bank” payments a year, well over 11 times the market share of card payments, the prospect of financial inclusion for all is virtually limitless,” says Pays.
“Our approach is completely open, and we want to partner with banks and other payments providers in each of the markets we enter,” he says. “We’ve taken the time to make sure our tech is ready for scalability, and we believe that moment has now arrived.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005804/en/
Contact information
Thomas Pays
thomas@ozow.com
+27 (74) 110-1011
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
